Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 978463, 15 pages
http://dx.doi.org/10.1155/2014/978463
Review Article

Obesity, Inflammation, and Lung Injury (OILI): The Good

1Department of Anesthesiology, University at Buffalo, State University of New York, 3435 Main Street, Buffalo, NY 14214, USA
2Veterans Affairs Western New York Healthcare System, Buffalo, NY 14215, USA

Received 17 February 2014; Accepted 19 March 2014; Published 11 May 2014

Academic Editor: Antonio Macciò

Copyright © 2014 Cheryl Wang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. A. Shaw, A. B. Caughey, and A. B. Edelman, “Obesity epidemic: how to make a difference in a busy OB/GYN practice,” Obstetrical & Gynecological Survey, vol. 67, no. 6, pp. 365–373, 2012. View at Publisher · View at Google Scholar
  2. K. M. Flegal, M. D. Carroll, C. L. Ogden, and L. R. Curtin, “Prevalence and trends in obesity among US adults, 1999–2008,” Journal of the American Medical Association, vol. 303, no. 3, pp. 235–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. N. Gong, E. K. Bajwa, B. T. Thompson, and D. C. Christiani, “Body mass index is associated with the development of acute respiratory distress syndrome,” Thorax, vol. 65, no. 1, pp. 44–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Lederer, S. M. Kawut, N. Wickersham et al., “Obesity and primary graft dysfunction after lung transplantation: the lung transplant outcomes group obesity study,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 9, pp. 1055–1061, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Gajic, O. Dabbagh, P. K. Park et al., “Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 4, pp. 462–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Mancuso, “Obesity and lung inflammation,” Journal of Applied Physiology, vol. 108, no. 3, pp. 722–728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. E. Hack, L. A. Aarden, and L. G. Thijs, “Role of cytokines in sepsis,” Advances in Immunology, vol. 66, pp. 101–195, 1997. View at Google Scholar · View at Scopus
  8. L. G. Thijs and C. E. Hack, “Time course of cytokine levels in sepsis,” Intensive Care Medicine, vol. 21, supplement 2, pp. S258–S263, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Bhatia and S. Moochhala, “Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome,” Journal of Pathology, vol. 202, no. 2, pp. 145–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. G. D. Rubenfeld, E. Caldwell, E. Peabody et al., “Incidence and outcomes of acute lung injury,” New England Journal of Medicine, vol. 353, no. 16, pp. 1685–1693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. L. K. Reiss, U. Uhlig, and S. Uhlig, “Models and mechanisms of acute lung injury caused by direct insults,” European Journal of Cell Biology, vol. 91, no. 6-7, pp. 590–601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Q. Simpson and L. C. Casey, “Role of tumor necrosis factor in sepsis and acute lung injury,” Critical Care Clinics, vol. 5, no. 1, pp. 27–47, 1989. View at Google Scholar · View at Scopus
  13. C. L. Klein, T. S. Hoke, W. Fang, C. J. Altmann, I. S. Douglas, and S. Faubel, “Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy,” Kidney International, vol. 74, no. 7, pp. 901–909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. V. D. O. Leal and D. Mafra, “Adipokines in obesity,” Clinica Chimica Acta, vol. 419, pp. 87–94, 2013. View at Publisher · View at Google Scholar
  15. J. M. Olefsky and C. K. Glass, “Macrophages, inflammation, and insulin resistance,” Annual Review of Physiology, vol. 72, pp. 219–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. Strieter, J. A. Belperio, and M. P. Keane, “Host innate defenses in the lung: the role of cytokines,” Current Opinion in Infectious Diseases, vol. 16, no. 3, pp. 193–198, 2003. View at Google Scholar · View at Scopus
  17. C. Herder, M. Carstensen, and D. M. Ouwens, “Anti-inflammatory cytokines and risk of type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 15, supplement 3, pp. 39–50, 2013. View at Google Scholar
  18. B. K. Tan, R. Adya, and H. S. Randeva, “Omentin: a novel link between inflammation, diabesity, and cardiovascular disease,” Trends in Cardiovascular Medicine, vol. 20, no. 5, pp. 143–148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Kralisch, J. Klein, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer, “Therapeutic perspectives of adipocytokines,” Expert Opinion on Pharmacotherapy, vol. 6, no. 6, pp. 863–872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. C. Calder, N. Ahluwalia, F. Brouns et al., “Dietary factors and low-grade inflammation in relation to overweight and obesity,” British Journal of Nutrition, vol. 106, supplement 3, pp. S5–S78, 2011. View at Google Scholar · View at Scopus
  21. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends in Endocrinology and Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. P. E. Scherer, S. Williams, M. Fogliano, G. Baldini, and H. F. Lodish, “A novel serum protein similar to C1q, produced exclusively in adipocytes,” Journal of Biological Chemistry, vol. 270, no. 45, pp. 26746–26749, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Shapiro and P. E. Scherer, “The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor,” Current Biology, vol. 8, no. 6, pp. 335–338, 1998. View at Google Scholar · View at Scopus
  24. R. Piñeiro, M. J. Iglesias, R. Gallego et al., “Adiponectin is synthesized and secreted by human and murine cardiomyocytes,” FEBS Letters, vol. 579, no. 23, pp. 5163–5169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Wang, W. B. Lau, E. Gao et al., “Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury,” American Journal of Physiology-Endocrinology and Metabolism, vol. 298, no. 3, pp. E663–E670, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Delaigle, M. Senou, Y. Guiot, M.-C. Many, and S. M. Brichard, “Induction of adiponectin in skeletal muscle of type 2 diabetic mice: in vivo and in vitro studies,” Diabetologia, vol. 49, no. 6, pp. 1311–1323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Van Berendoncks, A. Garnier, P. Beckers et al., “Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure,” Circulation: Heart Failure, vol. 3, no. 2, pp. 185–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. T. Turer and P. E. Scherer , “Adiponectin: mechanistic insights and clinical implications,” Diabetologia, vol. 55, no. 9, pp. 2319–2326, 2012. View at Publisher · View at Google Scholar
  29. H. Tilg and A. R. Moschen, “Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases,” Clinical Science, vol. 114, no. 3-4, pp. 275–288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. T. Turer, A. Khera, C. R. Ayers et al., “Adipose tissue mass and location affect circulating adiponectin levels,” Diabetologia, vol. 54, no. 10, pp. 2515–2524, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. R. Kizer, “A tangled threesome: adiponectin, insulin sensitivity, and adiposity: can mendelian randomization sort out causality?” Diabetes, vol. 62, no. 4, pp. 1007–1009, 2013. View at Publisher · View at Google Scholar
  32. J. Hoffstedt, E. Arvidsson, E. Sjölin, K. Wåhlén, and P. Arner, “Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1391–1396, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. B. Schulze, I. Shai, E. B. Rimm, T. Li, N. Rifai, and F. B. Hu, “Adiponectin and future coronary heart disease events among men with type 2 diabetes,” Diabetes, vol. 54, no. 2, pp. 534–539, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Padmalayam and M. Suto, “Role of adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy,” Current Pharmaceutical Design, vol. 19, no. 32, pp. 5755–5763, 2013. View at Publisher · View at Google Scholar
  35. D. M. Maahs, L. G. Ogden, J. K. Snell-Bergeon et al., “Determinants of serum adiponectin in persons with and without type 1 diabetes,” American Journal of Epidemiology, vol. 166, no. 6, pp. 731–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Leth, K. K. Andersen, J. Frystyk et al., “Elevated levels of high-molecular-weight adiponectin in type 1 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3186–3191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. K. Semple, N. H. Halberg, K. Burling et al., “Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies,” Diabetes, vol. 56, no. 6, pp. 1712–1717, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Sattar, G. Wannamethee, N. Sarwar et al., “Adiponectin and coronary heart disease: a prospective study and meta-analysis,” Circulation, vol. 114, no. 7, pp. 623–629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Landskroner-Eiger, B. Qian, E. S. Muise et al., “Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo,” Clinical Cancer Research, vol. 15, no. 10, pp. 3265–3276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Iwabu, T. Yamauchi, M. Okada-Iwabu et al., “Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca 2+ and AMPK/SIRT1,” Nature, vol. 464, no. 7293, pp. 1313–1319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Klöting, M. Fasshauer, A. Dietrich et al., “Insulin-sensitive obesity,” American Journal of Physiology-Endocrinology and Metabolism, vol. 299, no. 3, pp. E506–E515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Sun, C. M. Kusminski, and P. E. Scherer, “Adipose tissue remodeling and obesity,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2094–2101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Wang, L. M. Sparks, H. Xie, F. L. Greenway, L. De Jonge, and S. R. Smith, “Subtyping obesity with microarrays: implications for the diagnosis and treatment of obesity,” International Journal of Obesity, vol. 33, no. 4, pp. 481–489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Dietze-Schroeder, H. Sell, M. Uhlig, M. Koenen, and J. Eckel, “Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors,” Diabetes, vol. 54, no. 7, pp. 2003–2011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Awazawa, K. Ueki, K. Inabe et al., “Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway,” Cell Metabolism, vol. 13, no. 4, pp. 401–412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. W. L. Holland, R. A. Miller, Z. V. Wang et al., “Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin,” Nature Medicine, vol. 17, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. I. W. Asterholm and P. E. Scherer, “Enhanced metabolic flexibility associated with elevated adiponectin levels,” American Journal of Pathology, vol. 176, no. 3, pp. 1364–1376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. X. Xin, L. Zhou, C. M. Reyes, F. Liu, and L. Q. Dong, “APPL1 mediates adiponectin-stimulated p38 MAPK activation by scaffolding the TAK1-MKK3-p38 MAPK pathway,” American Journal of Physiology-Endocrinology and Metabolism, vol. 300, no. 1, pp. E103–E110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Hug, J. Wang, N. S. Ahmad, J. S. Bogan, T. Tsao, and H. F. Lodish, “T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 28, pp. 10308–10313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. J. R. Rao, D. J. Keating, C. Chen, and H. C. Parkington, “Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms,” Diabetes, Obesity and Metabolism, vol. 14, no. 11, pp. 983–989, 2012. View at Publisher · View at Google Scholar
  51. N. Wijesekara, M. Krishnamurthy, A. Bhattacharjee, A. Suhail, G. Sweeney, and M. B. Wheeler, “Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion,” Journal of Biological Chemistry, vol. 285, no. 44, pp. 33623–33631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Awazawa, K. Ueki, K. Inabe et al., “Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway,” Biochemical and Biophysical Research Communications, vol. 382, no. 1, pp. 51–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Ohashi, J. L. Parker, N. Ouchi et al., “Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype,” Journal of Biological Chemistry, vol. 285, no. 9, pp. 6153–6160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Luo, X. Wang, B. H. Chung et al., “Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo,” American Journal of Physiology-Endocrinology and Metabolism, vol. 301, no. 1, pp. E180–E186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Engeli, M. Feldpausch, K. Gorzelniak et al., “Association between adiponectin and mediators of inflammation in obese women,” Diabetes, vol. 52, no. 4, pp. 942–947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Krakoff, T. Funahashi, C. D. A. Stehouwer et al., “Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian,” Diabetes Care, vol. 26, no. 6, pp. 1745–1751, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Ouchi, S. Kihara, T. Funahashi et al., “Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue,” Circulation, vol. 107, no. 5, pp. 671–674, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance,” Science, vol. 259, no. 5091, pp. 87–91, 1993. View at Google Scholar · View at Scopus
  59. P. Mancuso, “Obesity and lung inflammation,” Journal of Applied Physiology, vol. 108, no. 3, pp. 722–728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Nakatsuji, H. Kobayashi, K. Kishida et al., “Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio,” Metabolism, vol. 62, no. 1, pp. 109–120, 2013. View at Publisher · View at Google Scholar
  61. T. Yamauchi, J. Kamon, Y. Ito et al., “Cloning of adiponectin receptors that mediate antidiabetic metabolic effects,” Nature, vol. 423, no. 762, p. 769, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. S. M. Sliman, R. B. Patel, J. P. Cruff et al., “Adiponectin protects against hyperoxic lung injury and vascular leak,” Cell Biochemistry and Biophysics, vol. 67, no. 2, pp. 399–414, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J. M. Konter, J. L. Parker, E. Baez et al., “Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation,” Journal of Immunology, vol. 188, no. 2, pp. 854–863, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. S. E. Orfanos, I. Mavrommati, I. Korovesi, and C. Roussos, “Pulmonary endothelium in acute lung injury: from basic science to the critically ill,” Intensive Care Medicine, vol. 30, no. 9, pp. 1702–1714, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Tsushima, L. S. King, N. R. Aggarwal, A. De Gorordo, F. R. D'Alessio, and K. Kubo, “Acute lung injury review,” Internal Medicine, vol. 48, no. 9, pp. 621–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. R. D. Stapleton, A. E. Dixon, P. E. Parsons, L. B. Ware, and B. T. Suratt, “The association between BMI and plasma cytokine levels in patients with acute lung injury,” Chest, vol. 138, no. 3, pp. 568–577, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. N. Gong, E. K. Bajwa, B. T. Thompson, and D. C. Christiani, “Body mass index is associated with the development of acute respiratory distress syndrome,” Thorax, vol. 65, no. 1, pp. 44–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Towfigh, M. V. Peralta, M. J. Martin et al., “Acute respiratory distress syndrome in nontrauma surgical patients: a 6-year study,” Journal of Trauma-Injury, Infection and Critical Care, vol. 67, no. 6, pp. 1239–1243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Anzueto, F. Frutos-Vivar, A. Esteban et al., “Influence of body mass index on outcome of the mechanically ventilated patients,” Thorax, vol. 66, no. 1, pp. 66–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. O. Gajic, O. Dabbagh, P. K. Park et al., “Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 4, pp. 462–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Shibata, K. Sato, D. R. Pimentel et al., “Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms,” Nature Medicine, vol. 11, no. 10, pp. 1096–1103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Summer, F. F. Little, N. Ouchi et al., “Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1035–L1042, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Rokni Yazdi, S. Lari, D. Attaran, H. Ayatollahi, and A. Mohsenizadeh, “The serum levels of adiponectin and leptin in mustard lung patients,” Human & Experimental Toxicology, 2013. View at Google Scholar
  74. A. J. Walkey, T. W. Rice, J. Konter et al., “Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure,” Critical Care Medicine, vol. 38, no. 12, pp. 2329–2334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. A. J. Walkey, T. W. Rice, J. Konter et al., “Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure,” Critical Care Medicine, vol. 38, no. 12, pp. 2329–2334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Garcia and A. Sood, “Adiponectin in pulmonary disease and critically ill patients,” Current Medicinal Chemistry, vol. 19, no. 32, pp. 5493–5500, 2012. View at Publisher · View at Google Scholar
  77. S. Leivo-Korpela, L. Lehtimäki, K. Vuolteenaho et al., “Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD,” Respiratory Medicine, vol. 108, no. 1, pp. 122–128, 2014. View at Google Scholar
  78. K. Ohashi, J. L. Parker, N. Ouchi et al., “Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype,” Journal of Biological Chemistry, vol. 285, no. 9, pp. 6153–6160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Summer, F. F. Little, N. Ouchi et al., “Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1035–L1042, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S. A. Shore, R. D. Terry, L. Flynt, A. Xu, and C. Hug, “Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice,” Journal of Allergy and Clinical Immunology, vol. 118, no. 2, pp. 389–395, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Aprahamian, R. G. Bonegio, C. Richez et al., “The peroxisome proliferator-activated receptor γ agonist rosiglitazone ameliorates murine lupus by induction of adiponectin,” Journal of Immunology, vol. 182, no. 1, pp. 340–346, 2009. View at Google Scholar · View at Scopus
  82. H. Nishizawa, L. Shimomura, K. Kishida et al., “Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein,” Diabetes, vol. 51, no. 9, pp. 2734–2741, 2002. View at Google Scholar · View at Scopus
  83. R. Z. Yang, M. Lee, H. Hu et al., “Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action,” American Journal of Physiology-Endocrinology and Metabolism, vol. 290, no. 6, pp. E1253–E1261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. G. Catli, A. Anik, A. Abaci, T. Kume, and E. Bober, “Low omentin-1 levels are related with clinical and metabolic parameters in obese children,” Experimental and Clinical Endocrinology & Diabetes, vol. 121, no. 10, pp. 595–600, 2013. View at Publisher · View at Google Scholar
  85. C. M. De Souza Batista, R. Yang, M. Lee et al., “Omentin plasma levels and gene expression are decreased in obesity,” Diabetes, vol. 56, no. 6, pp. 1655–1661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. P. Yan, D. Liu, M. Long, Y. Ren, J. Pang, and R. Li, “Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 4, pp. 257–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Saremi, M. Asghari, and A. Ghorbani, “Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men,” Journal of Sports Sciences, vol. 28, no. 9, pp. 993–998, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Y. Pan, L. Guo, and Q. Li, “Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 88, no. 1, pp. 29–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. J. M. Moreno-Navarrete, V. Cataln, F. Ortega et al., “Circulating omentin concentration increases after weight loss,” Nutrition and Metabolism, vol. 7, p. 27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. B. K. Tan, R. Adya, S. Farhatullah, J. Chen, H. Lehnert, and H. S. Randeva, “Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome,” Diabetes, vol. 59, no. 12, pp. 3023–3031, 2010. View at Publisher · View at Google Scholar
  91. A. Esteghamati, S. Noshad, S. Rabizadeh, M. Ghavami, A. Zandieh, and M. Nakhjavani, “Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial,” Regulatory Peptides, vol. 182, pp. 1–6, 2013. View at Publisher · View at Google Scholar
  92. A. Siejkaa, J. Jankiewicz-Wikaa, K. Kolomeckib et al., “Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity,” Cytokine, vol. 64, no. 2, pp. 490–493, 2013. View at Google Scholar
  93. A. Schäffler, M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler, “Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue,” Biochimica et Biophysica Acta-Gene Structure and Expression, vol. 1732, no. 1–3, pp. 96–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Šenolt, M. Polanská, M. Filková et al., “Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1410–1411, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. C. M. de Souza Batista, R. Yang, M. Lee et al., “Omentin plasma levels and gene expression are decreased in obesity,” Diabetes, vol. 56, no. 6, pp. 1655–1661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, “Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells,” Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 339–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Kazama, T. Usui, M. Okada, Y. Hara, and H. Yamawaki, “Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 686, no. 1–3, pp. 116–123, 2012. View at Publisher · View at Google Scholar
  98. X. Zhong, X. Li, F. Liu, H. Tan, and D. Shang, “Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway,” Biochemical and Biophysical Research Communications, vol. 425, no. 2, pp. 401–406, 2012. View at Publisher · View at Google Scholar
  99. K. Kazama, T. Usui, M. Okada, Y. Hara, and H. Yamawaki, “Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 686, no. 1–3, pp. 116–123, 2012. View at Publisher · View at Google Scholar
  100. H. Yamawaki, “Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses,” Biological and Pharmaceutical Bulletin, vol. 34, no. 3, pp. 307–310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Zirlik, K. Hildner, A. Targosz et al., “Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome?” Journal of Physiology and Pharmacology, vol. 64, no. 3, pp. 353–360, 2013. View at Google Scholar
  102. Q. Wang, X. Feng, C. Zhou, P. Li, and J. Kang, “Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome,” Annals of Clinical Biochemistry, vol. 50, part 3, pp. 230–235, 2013. View at Google Scholar
  103. O. K. Kurt, M. Tosun, A. Alcelik, B. Yilmaz, and F. Talay, “Serum omentin levels in patients with obstructive sleep apnea,” Sleep Breath, 2013. View at Google Scholar
  104. N. Ouchi, A. Higuchi, K. Ohashi et al., “Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity,” Science, vol. 329, no. 5990, pp. 454–457, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. D. M. Schulte, N. Müller, K. Neumann et al., “Pro-inflammatory wnt5a and anti-inflammatory sfrp5 are differentially regulated by nutritional factors in obese human subjects,” PLoS ONE, vol. 7, no. 2, Article ID e32437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Ehrlund, N. Mejhert, S. Lorente-Cebrián et al., “Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue,” Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 3, pp. E503–E508, 2013. View at Publisher · View at Google Scholar
  107. H. Mori, T. C. Prestwich, M. A. Reid et al., “Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition,” Journal of Clinical Investigation, vol. 122, no. 7, pp. 2405–2416, 2012. View at Google Scholar
  108. C. P. Xavier, M. Melikova, Y. Chuman, A. Uren, B. Baljinnyam, and J. S. Rubin, “Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/β-catenin signaling,” Cellular Signalling, vol. 26, no. 1, pp. 94–101, 2014. View at Publisher · View at Google Scholar
  109. J. Zhu, Y. Wang, J. Duan et al., “DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer,” Journal of Experimental & Clinical Cancer Research, vol. 31, p. 80, 2012. View at Publisher · View at Google Scholar
  110. M. Castro, L. Grau, P. Puerta et al., “Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer,” Journal of Translational Medicine, vol. 8, p. 86, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Y. Lee, B. He, L. You et al., “Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma,” Oncogene, vol. 23, no. 39, pp. 6672–6676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Hida, J. Wada, J. Eguchi et al., “Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10610–10615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Klöting, P. Kovacs, M. Kern et al., “Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects,” Diabetologia, vol. 54, no. 7, pp. 1819–1823, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. B. S. Youn, N. Klöting, J. Kratzsch et al., “Serum vaspin concentrations in human obesity and type 2 diabetes,” Diabetes, vol. 57, no. 2, pp. 372–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Schultz and A. G. Beck-Sickinger, “Chemerin and vaspin: possible targets to treat obesity?” ChemMedChem, vol. 8, no. 4, pp. 549–559, 2013. View at Publisher · View at Google Scholar
  116. A. Handisurya, M. Riedl, G. Vila et al., “Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss,” Obesity Surgery, vol. 20, no. 2, pp. 198–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Sell, A. Divoux, C. Poitou et al., “Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2892–2896, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. B. K. Tan, D. Heutling, J. Chen et al., “Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance,” Diabetes, vol. 57, no. 6, pp. 1501–1507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Morisaki, F. Takeshima, H. Fukuda et al., “High serum vaspin concentrations in patients with ulcerative colitis,” Digestive Diseases and Sciences, vol. 59, no. 2, pp. 315–521, 2013. View at Publisher · View at Google Scholar
  120. J. M. Kim, T. N. Kim, and J. C. Won, “Association between serum vaspin level and metabolic syndrome in healthy korean subjects,” Metabolic Syndrome and Related Disorders, vol. 11, no. 6, pp. 385–391, 2013. View at Publisher · View at Google Scholar
  121. H. Li, W. Peng, J. Zhuang et al., “Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-κB signaling pathways,” Atherosclerosis, vol. 228, no. 1, pp. 61–68, 2013. View at Publisher · View at Google Scholar
  122. P. Zahradka, “Inhibition of NADPH oxidase by vaspin may prevent progression of atherosclerosis,” Acta Physiologica, vol. 209, no. 3, pp. 195–198, 2013. View at Google Scholar
  123. J. K. Cho, T. Han, and H. S. Kang, “Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men,” European Journal of Applied Physiology, vol. 108, no. 2, pp. 347–353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Bing, Y. Bao, J. Jenkins et al., “Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2500–2505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. S. T. Russell and M. J. Tisdale, “Studies on the anti-obesity activity of zinc-α 2-glycoprotein in the rat,” International Journal of Obesity, vol. 35, no. 5, pp. 658–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. S. T. Russell and M. J. Tisdale, “Role of β-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-α2-glycoprotien (ZAG),” Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1821, no. 4, pp. 590–599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. C. Bing, “Lipid mobilization in cachexia: mechanisms and mediators,” Current Opinion in Supportive and Palliative Care, vol. 5, no. 4, pp. 356–360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Bing, T. Mracek, D. Gao, and P. Trayhurn, “Zinc-α2-glycoprotein: an adipokine modulator of body fat mass,” International Journal of Obesity, vol. 34, no. 11, pp. 1559–1565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. S. T. Russell and M. J. Tisdale, “Studies on the antiobesity effect of zinc-α 2-glycoprotein in the ob/ob mouse,” International Journal of Obesity, vol. 35, no. 3, pp. 345–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. D. M. Selva, A. Lecube, C. Hernández, J. A. Baena, J. M. Fort, and R. Simó, “Lower zinc-α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 11, pp. 4499–4507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Yang, R. Liu, S. Li et al., “Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes,” Diabetes Care, vol. 36, no. 5, pp. 1074–1082, 2013. View at Publisher · View at Google Scholar
  132. D. C. Yeung, K. S. Lam, Y. Wang, A. W. Tso, and A. Xu, “Serum zinc-α2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2531–2536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. C. C. Pelletier, L. Koppe, M. L. Croze et al., “White adipose tissue overproduces the lipid-mobilizing factor zinc α2-glycoprotein in chronic kidney disease,” Kidney International, vol. 83, no. 5, pp. 878–886, 2013. View at Publisher · View at Google Scholar
  134. D. Gao, P. Trayhurn, and C. Bing, “Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes,” Molecular and Cellular Endocrinology, vol. 325, no. 1-2, pp. 135–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. V. O. Leal, J. C. Lobo, M. B. Stockler-Pinto et al., “Is zinc-α2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis?” Clinica Chimica Acta, vol. 413, no. 5-6, pp. 616–619, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. T. Mracek, Q. Ding, T. Tzanavari et al., “The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity,” Clinical Endocrinology, vol. 72, no. 3, pp. 334–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. V. Ceperuelo-Mallafré, S. Näf, X. Escoté et al., “Circulating and adipose tissue gene expression of zinc-α2- glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 12, pp. 5062–5069, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. M. P. Marrades, J. A. Martínez, and M. J. Moreno-Aliaga, “ZAG, a lipid mobilizing adipokine, is downregulated in human obesity,” Journal of Physiology and Biochemistry, vol. 64, no. 1, pp. 61–66, 2008. View at Google Scholar · View at Scopus
  139. E. Hong, J. K. Hwi, Y. Cho et al., “Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle,” Diabetes, vol. 58, no. 11, pp. 2525–2535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. E. van Exel, J. Gussekloo, A. J. de Craen, M. Frölich, A. B. D. Wiel, and R. G. J. Westendorp, “Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-plus study,” Diabetes, vol. 51, no. 4, pp. 1088–1092, 2002. View at Google Scholar · View at Scopus
  141. C. Herder, M. Carstensen, and D. M. Ouwens, “Anti-inflammatory cytokines and risk of type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 15, supplement 3, pp. 39–50, 2013. View at Google Scholar
  142. J. Banchereau, V. Pascual , and A. O'Garra, “From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines,” Nature Immunology, vol. 13, no. 10, pp. 925–931, 2012. View at Publisher · View at Google Scholar
  143. M. L. Bustos, L. Huleihela, E. M. Meyer et al., “Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels,” Stem Cells Translational Medicine, vol. 2, no. 11, pp. 884–895, 2013. View at Publisher · View at Google Scholar
  144. H. Itano, W. Zhang, J. H. Ritter, T. J. McCarthy, T. Mohanakumar, and G. A. Patterson, “Adenovirus-mediated gene transfer of human interleukin 10 ameliorates reperfusion injury of rat lung isografts,” Journal of Thoracic and Cardiovascular Surgery, vol. 120, no. 5, pp. 947–956, 2000. View at Google Scholar · View at Scopus
  145. T. J. Standiford, R. M. Strieter, N. W. Lukacs, and S. L. Kunkel, “Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor,” Journal of Immunology, vol. 155, no. 4, pp. 2222–2229, 1995. View at Google Scholar · View at Scopus
  146. T. A. Grool, H. van Dullemen, J. Meenan et al., “Anti-inflammatory effect of interleukin-10 in rabbit immune complexinduced colitis,” Scandinavian Journal of Gastroenterology, vol. 33, no. 7, pp. 754–758, 1998. View at Publisher · View at Google Scholar · View at Scopus
  147. M. Kurte, M. López, A. Aguirre et al., “A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells,” Journal of Immunology, vol. 173, no. 3, pp. 1731–1737, 2004. View at Google Scholar · View at Scopus
  148. M. N. López, B. Pesce, M. Kurte et al., “A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-β+ tolerogenic dendritic cells,” Immunobiology, vol. 216, no. 10, pp. 1117–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. M. O. Osman, N. O. Jacobsen, J. U. Kristensen et al., “It 9302, a synthetic interleukin-10 agonist diminishes acute lung injury in rabbits with acute necrotizing pancreatitis,” Surgery, vol. 124, no. 3, pp. 584–592, 1998. View at Publisher · View at Google Scholar · View at Scopus
  150. M. O. Osman, B. Gesser, J. T. Mortensen, K. Matsushima, S. L. Jensen, and C. G. Larsen, “Profiles of pro-inflammatory cytokines in the serum of rabbits after experimentally induced acute pancreatitis,” Cytokine, vol. 17, no. 1, pp. 53–59, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Carstensen, C. Herder, M. Kivimäki et al., “Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study,” Diabetes, vol. 59, no. 5, pp. 1222–1227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-receptor antagonist in type 2 diabetes mellitus,” New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. E. J. P. van Asseldonk, R. Stienstra, T. B. Koenen, L. A. B. Joosten, M. G. Netea, and C. J. Tack, “Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 2119–2126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. I. Aksentijevich, S. L. Masters, P. J. Ferguson et al., “An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist,” New England Journal of Medicine, vol. 360, no. 23, pp. 2426–2437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Herold, T. Tabar, H. Janßen et al., “Exudate macrophages attenuate lung injury by the release of IL-1 receptor antagonist in gram-negative pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 10, pp. 1380–1390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. J. Banchereau, V. Pascual, and A. O'Garra, “From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines,” Nature Immunology, vol. 13, no. 10, pp. 925–931, 2012. View at Google Scholar
  157. M. O. Li and R. A. Flavell, “Contextual regulation of inflammation: a duet by transforming growth factor-β and interleukin-10,” Immunity, vol. 28, no. 4, pp. 468–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. N. Zamani and C. W. Brown, “Emerging roles for the transforming growth factor-β superfamily in regulating adiposity and energy expenditure,” Endocrine Reviews, vol. 32, no. 3, pp. 387–403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. T. Kempf, A. Guba-Quint, J. Torgerson et al., “Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial,” European Journal of Endocrinology, vol. 167, no. 5, pp. 671–678, 2012. View at Publisher · View at Google Scholar
  160. G. Vila, M. Riedl, C. Anderwald et al., “The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients,” Clinical Chemistry, vol. 57, no. 2, pp. 309–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. L. Macia, V. Tsai, A. D. Nguyen et al., “Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets,” PLoS ONE, vol. 7, no. 4, Article ID e34868, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. K. Yanaba, Y. Asano, Y. Tada, M. Sugaya, T. Kadono, and S. Sato, “Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity,” Modern Rheumatology, vol. 22, no. 5, pp. 668–675, 2012. 22(5): p. 668-675. View at Publisher · View at Google Scholar · View at Scopus
  163. L. Otvos Jr., E. Haspinger, F. LaRussa et al., “Design and development of a peptide-based adiponectin receptor agonist for cancer treatment,” BMC Biotechnology, vol. 11, p. 90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. M. O. Osman, N. O. Jacobsen, J. U. Kristensen et al., “It 9302, a synthetic interleukin-10 agonist diminishes acute lung injury in rabbits with acute necrotizing pancreatitis,” Surgery, vol. 124, no. 3, pp. 584–592, 1998. View at Publisher · View at Google Scholar · View at Scopus
  165. M. N. López, B. Pesce, M. Kurte et al., “A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-β+ tolerogenic dendritic cells,” Immunobiology, vol. 216, no. 10, pp. 1117–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus